Shukra Pharmaceuticals (524632) Q1 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended June 30, 2024, at the meeting held on August 12, 2024.

• Statutory auditors provided a limited review report with no material misstatements identified.

Financial highlights

• Revenue from operations for Q1 FY25 was ₹317.80 lakhs, down from ₹1,088.39 lakhs in Q4 FY24 and ₹2,016.01 lakhs in Q1 FY24.

• Net profit for Q1 FY25 stood at ₹48.53 lakhs, compared to ₹398.59 lakhs in Q4 FY24 and ₹42.03 lakhs in Q1 FY24.

• Total expenses for Q1 FY25 were ₹309.89 lakhs, significantly lower than ₹703.72 lakhs in Q4 FY24 and ₹2,036.70 lakhs in Q1 FY24.

• Basic and diluted EPS for Q1 FY25 was ₹0.11, compared to ₹3.64 in Q4 FY24 and ₹0.59 in Q1 FY24.

Key financial ratios and metrics

• Gross margin improved due to lower expenses, despite a sharp decline in revenue year-over-year.

• Profit before tax for Q1 FY25 was ₹79.67 lakhs, down from ₹522.35 lakhs in Q4 FY24 but up from ₹42.67 lakhs in Q1 FY24.